Garadacimab Biosimilar - Anti-F12 mAb - Research Grade
Source
CAS 2162134-62-3
Species
Humanized
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Garadacimab ,CSL312,F12,anti-F12
Reference
PX-TA1560
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
IgG4-lambda
Clonality
Monoclonal Antibody
Description of Garadacimab Biosimilar - Anti-F12 mAb - Research Grade
Introduction
Garadacimab Biosimilar, also known as Anti-F12 mAb, is a research grade monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody, Garadacimab. It is a highly specific and potent antibody that targets the F12 protein, making it a promising therapeutic option for various diseases.
Structure of Garadacimab Biosimilar
Garadacimab Biosimilar is a recombinant humanized monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains consist of 450 amino acids, while the light chains have 214 amino acids. The antibody has a molecular weight of approximately 150 kDa.
Activity of Garadacimab Biosimilar
Garadacimab Biosimilar specifically binds to the F12 protein, which is a component of the coagulation pathway. It inhibits the activation of Factor XII, a key player in the blood clotting process. By blocking the activity of F12, Garadacimab Biosimilar prevents the formation of blood clots, making it a potential therapeutic option for thrombotic disorders.
Application of Garadacimab Biosimilar
Garadacimab Biosimilar has shown promising results in pre-clinical studies for the treatment of thrombotic disorders such as deep vein thrombosis and pulmonary embolism. It has also shown potential in the prevention of thrombotic events in patients undergoing major surgeries. Additionally, Garadacimab Biosimilar has been explored as a potential treatment for other diseases such as stroke, myocardial infarction, and sepsis.
Advantages of Garadacimab Biosimilar
As a biosimilar of Garadacimab, the advantages of Garadacimab Biosimilar include its high specificity and potency, as well as its lower cost compared to the original therapeutic antibody. Being a research grade antibody, it also offers a cost-effective option for pre-clinical studies and research purposes.
Conclusion
In summary, Garadacimab Biosimilar is a promising research grade antibody that specifically targets the F12 protein and has shown potential as a therapeutic option for thrombotic disorders. Its structure, activity, and potential applications make it a valuable tool for researchers and a potential treatment option for patients in the future. Further studies and clinical trials are needed to fully understand the efficacy and safety of Garadacimab Biosimilar, but its potential as a therapeutic antibody is promising.
SDS-PAGE for Garadacimab Biosimilar - Anti-F12 mAb
Garadacimab Biosimilar - Anti-F12 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Reviews
Rated 5 out of 5
Dr. Arup Bhattacharya –
In which application did you use the antibody?: other
Did it work in your application?: Yes
Excellent antibody that we use for invivo studies in mice to replace Enoxaparin and saw it was able to neutralize F12 in vivo.
Would recommend for service friendliness and product quality!!
Dr. Arup Bhattacharya –
In which application did you use the antibody?: other
Did it work in your application?: Yes
Excellent antibody that we use for invivo studies in mice to replace Enoxaparin and saw it was able to neutralize F12 in vivo.
Would recommend for service friendliness and product quality!!